Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 43Carcinoma, Hepatocellular 19Rectal Neoplasms 10Colonic Neoplasms 10Neoplasm Metastasis 9Gastrointestinal Stromal Tumors 8Sarcoma 5Ovarian Neoplasms 5Cholangiocarcinoma 5Melanoma 4Pancreatic Neoplasms 3Osteosarcoma 3Liver Neoplasms 3Glioblastoma 3Stomach Neoplasms 2Neoplasms 2Lung Neoplasms 2Gallbladder Neoplasms 2Fatigue 2Esophageal Neoplasms 2Colorectal Cancer Metastatic 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bile Duct Neoplasms 2Adenocarcinoma 2Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) 1Thyroid Neoplasms 1Thymoma 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1

Interventions

regorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Solid Malignant Tumors × regorafenib × Clear all
NCT06246643 2026-05-19

A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

Bayer

Phase 2 Active not recruiting
13 enrolled

Solid Malignant Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡